Samsara BioCapital

Activity in this selectiontaiho-ventures-5087b202

By stage

Series B3

Series C+2

Biotech5

United States5

5 in this selection

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Apr 8

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed

Mar 31

Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders

$100MSeries B

Role not disclosed

Jan 8

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries B

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed